Hepatitis C and kidney transplant: The eradication time of the virus has arrived

Area of Science:

• Hepatology
• Transplant Surgery
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection significantly reduces patient and graft survival in renal transplant (RT) recipients.
• Previous treatments like interferon were contraindicated in kidney transplant patients due to safety concerns.

Purpose of the Study:

• To evaluate the impact of directly acting antivirals (DAAs) on HCV eradication in renal transplant recipients.
• To explore the potential of using DAAs to manage HCV in patients with varying degrees of kidney insufficiency and liver disease.

Main Methods:

• Review of studies on DAAs efficacy and safety in renal transplant patients with HCV.
• Analysis of DAA effectiveness across different HCV genotypes and patient renal function statuses.

Main Results:

• DAAs demonstrate high efficacy and an excellent safety profile for HCV eradication in kidney transplant patients, irrespective of genotype or renal insufficiency.
• DAAs represent a revolutionary treatment, offering a safe and effective alternative to interferon for this population.

Conclusions:

• DAAs have transformed HCV management in renal transplant recipients, enabling viral eradication and improving outcomes.
• The success of DAAs raises the possibility of utilizing kidneys from HCV-positive donors for transplantation, expanding the donor pool and improving access to RT.